Cerus (CERS) Says Hemolife Now Offering INTERCEPT-Treated pathogen Reduced Platelet Units
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Cerus Corporation (Nasdaq: CERS) announced that Hemolife Fundación Banco Nacional de Sangre (Hemolife) is now offering INTERCEPT-treated pathogen reduced platelet units to its hospitals. Hemolife, the first blood center to enter into routine use with INTERCEPT in Colombia, distributes approximately 12,000 platelet units to hospitals annually.
“Transmission of pathogens via blood transfusion is a significant threat throughout Latin America, with serious outbreaks of viruses such as Zika, dengue, and chikungunya becoming more prevalent,” commented William “Obi” Greenman, Cerus’ president and chief executive officer. “Hemolife is an organization at the forefront of transfusion medicine in Colombia. Adding INTERCEPT allows them to offer their hospitals a product that is proactively protected against these types of pathogens that have the potential to harm patients.”
The INTERCEPT Blood System leverages the fact that platelets and plasma do not require functional DNA or RNA, as opposed to pathogens and donor white blood cells. Pathogen reduction via the INTERCEPT Blood System is designed to block the replication process so that harmful viruses, bacteria, and parasites can no longer replicate and cause disease.
“This technology represents a leap forward in safeguarding the blood supply against harmful pathogens, which fits with our mission to take advantage of the latest technological advances in transfusion medicine,” commented Dr. Miguel German Rueda, president of the board of Hemolife foundation. “We are proud to provide INTERCEPT-treated platelets to hospitals in Colombia.”
In November 2015, the INTERCEPT Blood System for platelets and plasma received approval from the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) for commercial use in Colombia. Cerus is partnered with Laboratories Dai de Colombia S.A. for the sales, deployment, and support of the INTERCEPT Blood System in Colombia.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY), Ono Enter Settlement and License Agreement with Merck (MRK) to Resolve PD-1 Antibody Patent Litigation
- Rennova Health (RNVA) Says Genomas Subsidiary Granted Patent
- Seagate Technology (STX) Appoints Mark Adams to Board of Directors
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!